Home
Toolbox
Resource
Workflow
Tutorials
Citations
Downloads
Mutation Al-Predictor Flow
Gene-to-Mutation Flow
News & Insights
Genetic Encyclopedia
Frontiers
Industry Insights
Case Studies
About Us
About the Site
Contact Us
Private Policy
User Agreement
COL4A5 c.1390G>A
ALS1
DMD c.1332-11868C>G
TP53
肌萎缩侧索硬化症1型
USH2A c.8559-2A>G
囊性纤维化
Log In
|
Sign Up
中文
人类
HAVCR2 - Hepatitis A Virus Cellular Receptor 2
Alias:
TIM3
CD366
KIM-3
SPTCL
TIMD3
Tim-3
TIMD-3
HAVcr-2
Create a favorites folder
Cancel
Confirm
Add To Favorites
Select a favorites
Description
New favorites >>
Cancel
Confirm
Favorite
Basic Information
Sequence Homology
Related Diseases and Mutations
Transcripts & Proteins
Gene Expression
Interactions
Related Mouse Models
Related Drugs
References Literature
这个基因编码的蛋白质属于免疫球蛋白超家族和TIM蛋白质家族。根据其细胞因子分泌模式,CD4阳性T辅助淋巴细胞可分为1型(Th1)和2型(Th2)。Th1细胞涉及细胞介导的对内源性病原体的免疫和延迟性超敏反应,而Th2细胞涉及对体外寄生虫感染的控制以及促进特应性和过敏性疾病。这种蛋白质是一种Th1特异性的细胞表面蛋白质,可调节巨噬细胞的激活,并抑制Th1介导的自身和同种免疫应答,促进免疫耐受。[由RefSeq,2011年9月提供]
Related ID:
NCBI:84868
ENSEMBL:ENSG00000135077
HGNC:18437
UNIPROT:Q8TDQ0
OMIM:606652
Basic Information
NCBI
Transcripts
Exons
Length
MW (kDa)
Mutations
Related Diseases
Related Mouse Models
Reference
84868
1
7
23213 bp
33.39
22
1
12
23
HAVCR2 Genetics information (-)
GRCh38
Sequence Homology
Related Diseases and Mutations
#
Disease
Anatomical Category
Score
Mutations
No data available
Transcripts & Proteins
Table View
Tile View
#
Transcript
Length(nt)
Exon Count
CDS(bp)
Protein
Length(aa)
No data available
* This data comes from NCBI.
Gene Expression
Tissue-specific RNA expression
Organ
Abundance
Alphabetical
Cell-specific RNA expression
Organ
Abundance
Alphabetical
Interactions
Reset
Acting
Regulation
Detail
Mechanism
Target
Residues
Reference
Score
No data available
Related Mouse Models
Type
Name
MGI
Strain of Origin
Publications
Mutations
No data available
Related Drugs
Name
CAS Number
Status
Phase
Link
No data available
References Literature
Title
PMID
Journal
Year
IF
No Data Found!
Wechat
Mutation Direct
Sequence
Comparison
Al agent
Tutorials
Back to top